European Pharmaceutical Review

APRIL 12, 2024

billion, the agreement seeks to advance in vivo therapies for targets that cause serious neurological and neuromuscular diseases. The increasing presence of CRISPR-based therapies in clinical trials is anticipated to fuel further advancements in precision medicine,” Chan stated. In a deal potentially worth over $1.57

Food and Drug Administration 84

Food and Drug Administration Medicine Food Pharmaceutical 84

Pharmaceutical Technology

APRIL 17, 2023

At the meeting , Indiana University’s School of Medicine neurology professor Dr. Liana Apostolova said that Rexulti demonstrated statistical significance and resulted in a clinically meaningful therapeutic effect. As a member of the committee, Apostolova voted in favour of Rexulti, adding that she was convinced by the clinical data.

FDA 96

FDA Safety Food Medicine 96

Pharmaceutical Technology

MAY 12, 2023

The partnership will combine Angelini Pharma’s expertise in neurological diseases with the scientific and technological strengths of JCR Pharmaceuticals for delivering biotherapeutics across the blood-brain barrier. Angelini Pharma CEO Jacopo Andreose stated: “Epilepsy is one of the most prevalent chronic neurological diseases.

Pharma 52

Pharma Pharmaceutical Patients 52

European Pharmaceutical Review

MARCH 8, 2023

A placebo-controlled, Phase IIa, proof-of-concept, social anxiety clinical trial is expected to begin in the first half of 2023. An open-label, Phase IIa, proof-of-concept clinical trial in women with PPD is expected to initiate in the second half of 2023. The results are anticipated by the end of 2023.

Transportation 91

Transportation Medical Pharmaceutical 91

Legacy MEDSearch

DECEMBER 14, 2022

NeurOptics’ Neurological Pupil index (NPi®) and automated pupillometry are now included in the updated 2021 European Resuscitation Council (ERC) and European Society of Intensive Care Medicine (ESICM) Guidelines for post-resuscitation care as an objective measurement supporting neurological prognosis in patients following cardiac arrest.

Medicine 52

Medicine Recruitment Medical Patients 52

European Pharmaceutical Review

DECEMBER 8, 2023

Cerevel’s pipeline includes multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease, and mood disorders. Gonzalez, chairman and chief executive officer of AbbVie.

Safety 95

Safety FDA Management Pharmaceutical 95

Pharmaceutical Technology

MARCH 23, 2023

BHV-8000’s mechanistic proof of concept was showed in several pre-clinical models. We look forward to advancing BHV-8000 into clinical development and uncovering the potential of neuroimmunomodulation for severe neurological disorders in desperate need of novel treatment options.”

Safety 105

Safety Pharmaceutical 105

European Pharmaceutical Review

APRIL 27, 2023

Through pre-clinical and clinical trial success, adeno-associated viral vectors (AAVs) have consistently demonstrated their effectiveness as a tool for gene delivery to treat a variety of human diseases. Since Glybera’s approval, two more AAVs have come on the market targeting neurological and ophthalmological diseases.

Biopharma 88

Biopharma Medicine Manufacturing Patients 88

Legacy MEDSearch

SEPTEMBER 14, 2023

The easy-to-use device makes it simple for patients to participate in clinically-validated, EEG-based sleep monitoring at home, unlocking new insights into sleep physiology. A clinical usability study demonstrated that the Dreem 3S is both well-tolerated by users and produces clinical-grade data in the home environment.

FDA 52

FDA Recruitment Medical Patients 52

pharmaphorum

NOVEMBER 15, 2022

Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-ranging push across cancer, immune-mediated, and neurological diseases.

Transportation 97

Transportation Pharma Management Leads 97

European Pharmaceutical Review

NOVEMBER 18, 2022

Upstaza is administered through a minimally invasive neurosurgical stereotactic procedure used to treat several neurological disorders in paediatric and adult patients. Upstaza clinical trials. The efficacy and safety profile of Upstaza has been shown across clinical trials and compassionate use programmes.

Side effects 126

Side effects Biopharma Safety Patients 126

pharmaphorum

DECEMBER 11, 2022

He sat down with pharmaphorum at Frontiers Health 2022 in Milan to discuss how his group approaches digital innovation around neurological diseases. Some symptoms of neurological diseases are very subjective, and evaluation timepoints are spread out over long periods of time. “We AI gets us closer to personalised medicine.”.

Patients 130

Patients Healthcare Healthcare Medical 130

European Pharmaceutical Review

NOVEMBER 2, 2022

The clinic will develop pre-clinical studies into early and late phase clinical trials to identify US Food and Drug Administration (FDA)-approved advanced regenerative medicines. The organisation considers collaboration will advance scientific discovery, clinical advances and training. Scientific and operational teams.

Food and Drug Administration 86

Food and Drug Administration Medicine Training Electronics 86

Pharmaceutical Technology

NOVEMBER 3, 2022

The funding will be used for the Phase III clinical trial and potential marketing of the investigational compound, ecopipam, for treating Tourette syndrome patients. The financing comes after the company reported positive data from the Phase IIb D1AMOND clinical trial where ecopipam was shown to reduce motor and phonic tics versus placebo. .

Food and Drug Administration 52

Food and Drug Administration Side effects Food Patients 52

European Pharmaceutical Review

AUGUST 24, 2023

Inhibikase is advancing its 201 trial evaluating risvodetinib at 50, 100 and 200mg to treat the neurological condition. Inhibikase Therapeutics submitted two Investigational New Drug (IND) applications in February 2019 to start the clinical development in multiple classes of Parkinson’s disease patients.

Safety 89

Safety Medical Medicine Patients 89

World of DTC Marketing

DECEMBER 22, 2021

According to the American Society of Clinical Oncology Journal , “the remarkable frequency of delays and disruptions in health care mostly related to the reduction of the COVID-19 burden unintentionally posed a major risk on cancer care worldwide. Many patients are shunning hospitals and clinics.

Patients 241

Patients Doctors Healthcare Healthcare 241

Legacy MEDSearch

AUGUST 16, 2023

The NTAP reimbursement program recognizes new technologies that provide substantially improved clinical benefit over currently available therapies, giving Medicare beneficiaries timely access to advancements in healthcare. These seizures increase the risk of permanent brain injury with long-term neurological disability 2,3.

FDA 52

FDA Food and Drug Administration Healthcare Provider Recruitment 52

Pharmaceutical Technology

JULY 6, 2022

Scientists at the National Institutes of Health (NIH) unit National Institute of Neurological Disorders and Stroke (NINDS) have found that Covid-19-induced immune response could damage the blood vessels of the brain and may lead to short and long-term neurological symptoms. .

Leads 64

Leads Patients Pharmaceutical 64

Legacy MEDSearch

SEPTEMBER 18, 2023

a clinical-stage, medical device company developing novel treatments for neurological diseases, announced that the U.S. is a clinical stage, medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. CereVasc, Inc., Carl Heilman, M.D., Are you hiring?

Food and Drug Administration 52

Food and Drug Administration FDA Patients Recruitment 52

pharmaphorum

JUNE 24, 2022

There was also a statistically significant improvement in neurological scores in people who had this type of symptom at enrolment at four weeks compared to standard care, although the two groups were equivalent on this measure at the 48-week timepoint. Symptom data mixed.

Side effects 73

Side effects Doctors Patients Medical 73

European Pharmaceutical Review

FEBRUARY 29, 2024

A key challenge in treating rare diseases is that “patient populations are so small that patients struggle to find a diagnosis and in turn it is difficult to recruit clinical trials. Toby plays a key role in developing ALS clinical trials, and in driving preclinical strategy within neurodegenerative and neuromuscular diseases.

Medicine 72

Medicine Patients Recruitment Training 72

European Pharmaceutical Review

AUGUST 17, 2023

In the PROGRESS clinical trial , the study demonstrated that 40 percent of its 778 participants achieved at least a 50 percent reduction in mean monthly migraine days (MMDs). In the ADVANCE clinical trial, which evaluated 910 patients, data showed that 59 percent of patients achieved at least a 50 percent reduction in MMDs.

Patients 80

Patients Pharma Medical Pharmaceutical 80

Pharmaceutical Technology

MAY 9, 2023

Biotechnology company Neuro3 Therapeutics has signed an exclusive worldwide licence and option agreement with pharmaceutical firm Lundbeck to develop and commercialise clinical stage KCNQ2 activators. The company will also handle the further development of these programmes through clinical proof-of-concept (PoC).

Pharmaceutical 52

Pharmaceutical 52

European Pharmaceutical Review

JUNE 27, 2023

Therefore “ACI-24.060 holds great promise as a novel therapy that can lower Abeta plaques to delay, or perhaps even prevent, the onset of clinical dementia symptoms in Alzheimer’s and Down’s syndrome-related Alzheimer’s,” Dr Rafii added.

Food and Drug Administration 94

Food and Drug Administration Safety FDA Food 94

pharmaphorum

AUGUST 2, 2022

Sosei Heptares has signed up a string of big pharma collaborators over the last few years, and one of them – AbbVie – has just expanded its partnership with a new to deal to apply the biotech’s G protein-coupled receptor (GPCR) expertise to the discovery of drugs for neurological diseases.

Pharma 75

Pharma Marketing Medicine 75

European Pharmaceutical Review

DECEMBER 14, 2022

Clinical-stage biopharmaceutical company Praxis Precision Medicines is translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterised by neuronal excitation-inhibition imbalance. Clinical success begins early for small molecule drugs.

Medicine 92

Medicine Sales Pharmaceutical 92

Pharmaceutical Technology

AUGUST 2, 2022

Sosei Heptares , a corporate brand of Sosei Group Corporation, has signed a new drug discovery partnership and option-to-license agreement with AbbVie for discovering, developing and marketing new therapies for neurological ailments. On signing of the deal, AbbVie will make an upfront payment of $40m to Sosei Heptares.

Sales 59

Sales Pharmaceutical Marketing 59

Legacy MEDSearch

DECEMBER 12, 2022

” Clinical studies have shown Nerivio to be as effective as standard of care pharmacological options for acute migraine treatment. When making their reimbursement decisions, they are looking at the actual clinical effectiveness and medical benefit exhibited by each therapy,” said Alon Ironi, CEO of Theranica.

Side effects 98

Side effects Insurance FDA Pharmacology 98

Pharmaceutical Technology

APRIL 19, 2023

Bayer has announced that it will shift the focus of its drug research away from women’s health to four core therapeutic areas: oncology, cardiovascular, neurology and rare diseases/immunology.

Healthcare 52

Healthcare Healthcare Leads Pharmaceutical 52

European Pharmaceutical Review

JANUARY 15, 2024

Previous research, including a 2022 paper published in JAMA Neurology , have highlighted the treatment’s potential to ‘dissociate’ efficacy from steroid safety concerns. Vamorolone’s mechanism of action According to Santhera, vamorolone binds to the same receptor as glucocorticoids, but its downstream activity is modified.

Medicine 100

Medicine Safety Patients Pharmaceutical 100

Pharmaceutical Technology

APRIL 18, 2023

PIPE-307 has already been evaluated in two Phase I clinical trials in healthy patients, and has also received Food and Drug Administration (FDA) clearance as an investigational new drug (IND) to commence its clinical development in patients with relapsing-remitting multiple sclerosis (RRMS).

Food and Drug Administration 52

Food and Drug Administration Food FDA Patients 52

Pharmaceutical Technology

MAY 1, 2023

“This milestone is a testament to advancing our robust biopharmaceutical pipeline of innovative medicines that aim to support more people living with mental health disorders and neurological diseases in the coming years.” Uzedy reduced the risk of schizophrenia relapse by up to 80% compared to placebo in a Phase III clinical trial.

Food and Drug Administration 75

Food and Drug Administration FDA Food Medicine 75

European Pharmaceutical Review

MARCH 30, 2023

These cells can quickly spread throughout the CSF and cause a variety of neurological symptoms. Until recently there have been limited resources to develop clinical trials in this space,” commented corresponding author Dr Isabella Glitza Oliva, PhD, Associate Professor of Melanoma Medical Oncology. “We

Side effects 82

Side effects Patients Medicine Leads 82

Pharmaceutical Technology

JUNE 16, 2023

The deal is aimed at advancing life sciences across three strategic areas: clinical and translational research, capacity building and technology transfer, and in the area of commercialisation.

Medicine 52

Medicine Healthcare Healthcare Education 52

Pharmaceutical Technology

NOVEMBER 29, 2022

PharmaTher also has an agreement in place with Case Western Reserve University to develop ketamine as a treatment for Rett syndrome, a rare genetic neurological disorder. Studying certain neurological conditions also comes with inherent challenges. The company now plans to move this approach into a Phase III trial.

Side effects 110

Side effects Pharmaceutical Patients Medicine 110

Pharmaceutical Technology

OCTOBER 4, 2022

Treatments to enhance the lives of debilitating neurological and neuropsychiatric disease patients are part of Biohaven’s portfolio. Additionally, Pfizer will gain access to a portfolio of pre-clinical CGRP assets of Biohaven with the takeover. With the takeover, Biohaven became a wholly-owned Pfizer subsidiary.

Biopharma 106

Biopharma Food and Drug Administration Medicine FDA 106

Pharmaceutical Technology

DECEMBER 15, 2022

The alliance will merge the capabilities of the scientists at Washington University in the basic and clinical research in neurodegenerative ailments, such as dementia, with the wide-ranging expertise of Eisai in discovering and developing drugs. By collaborating with world-leading research institutions such as Washington University in St.

Medicine 98

Medicine Safety Sales Leads 98